source
- RevMed's Rasonque shows weaker response in common KRAS pancreatic cancer mutation, shares fall over 6%New data from Revolution Medicines indicates that its KRAS inhibitor Rasonque had a reduced response rate in patients whose pancreatic tumors carry the most common KRAS mutation. The subgroup resp…
- TRexBio and Retension raise $161.7M in IPOs as biotech fundraising surge continuesTRexBio and Retension Pharmaceuticals are slated to begin trading on Friday, together raising $161.7 million. Their offerings push the number of biotech IPOs this year to 29, underscoring a continu…